Literature DB >> 27425222

Surgical Outcomes of Lobular Neoplasia Diagnosed in Core Biopsy: Prospective Study of 316 Cases.

Barbara Susnik1, Deborah Day2, Ellen Abeln3, Tara Bowman2, Janet Krueger4, Karen K Swenson5, Michaela L Tsai4, Margit L Bretzke6, Tamera J Lillemoe1.   

Abstract

BACKGROUND: Management recommendations for lobular neoplasia (LN) including lobular carcinoma-in-situ (LCIS) and atypical lobular hyperplasia (ALH) diagnosed in core biopsies (CB) are controversial. Our aim was to prospectively identify a subset of patients who do not require subsequent surgical excision (SE). PATIENTS AND METHODS: All patients diagnosed with LN on CB were enrolled and referred for SE. Cases with coexistent ductal carcinoma-in-situ or invasive carcinoma were excluded. Cases with coexistent ductal atypia (LN-DA) and LCIS variants (LN-V) were separated from pure classic LN (LN-C). Dedicated breast pathologists and radiologists reviewed cases with careful imaging/pathology correlation.
RESULTS: Of 13,772 total percutaneous breast CB procedures, 302 of 370 patients diagnosed with LN underwent SE. Upgrade to carcinoma was present in 3.5% (8/228) LN-C, 26.7% LN-V (4/15), and 28.3% LN-DA (15/53). Calcifications were the imaging target for 180 (79%) of 228 LN-C cases; 7 were associated with upgrade (3.9%). Upgrades were rare for mass lesions (1/32) and magnetic resonance imaging-targeted lesions (0/14). Upgrades were similar for ALH and LCIS (3.4% vs. 4.5%). During postsurgical follow-up (mean, 34.5 months), 6.5% LN-C patients developed carcinoma in either breast.
CONCLUSION: Although LN with nonclassic morphology or with associated ductal atypia requires SE, this can be avoided in LN-C diagnosed on CB targeting calcifications when careful imaging/pathology correlation is applied. Until larger numbers are studied, excising LN-C diagnosed as masses or magnetic resonance imaging-detected lesions may be prudent. Regardless of their selection for surgical management, LN patients need close surveillance in view of their long-term risk of breast cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical lobular hyperplasia; Breast cancer; Imaging pathology correlation; Lobular carcinoma in situ; Upgrade

Mesh:

Year:  2016        PMID: 27425222     DOI: 10.1016/j.clbc.2016.06.003

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  12 in total

1.  Outcomes of classic lobular neoplasia diagnosed on breast core needle biopsy: a retrospective multi-center study.

Authors:  Iskender Sinan Genco; Bugra Tugertimur; Qing Chang; Lauren Cassell; Sabina Hajiyeva
Journal:  Virchows Arch       Date:  2019-11-27       Impact factor: 4.064

2.  Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations.

Authors:  Beth T Harrison; Faina Nakhlis; Deborah A Dillon; T Rinda Soong; Elizabeth P Garcia; Stuart J Schnitt; Tari A King
Journal:  Mod Pathol       Date:  2020-01-13       Impact factor: 7.842

Review 3.  American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications.

Authors:  Stuart J Schnitt; Edi Brogi; Yunn-Yi Chen; Tari A King; Sunil R Lakhani
Journal:  Ann Diagn Pathol       Date:  2020-02-15       Impact factor: 2.090

Review 4.  The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS.

Authors:  Edi Brogi
Journal:  Virchows Arch       Date:  2022-05-14       Impact factor: 4.064

5.  Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma.

Authors:  Isabelle L Crary; Elizabeth U Parker; Kathryn P Lowry; Pranav P Patwardhan; Thing Rinda Soong; Sara H Javid; Kristine E Calhoun; Meghan R Flanagan
Journal:  Ann Surg Oncol       Date:  2022-07-08       Impact factor: 4.339

Review 6.  Lobular carcinoma in situ: diagnostic criteria and molecular correlates.

Authors:  Anna Sokolova; Sunil R Lakhani
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

Review 7.  Lobular Carcinoma In Situ.

Authors:  Hannah Y Wen; Edi Brogi
Journal:  Surg Pathol Clin       Date:  2017-12-08

8.  Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.

Authors:  Eliah R Shamir; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2020-01-06       Impact factor: 7.842

9.  Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.

Authors:  M Gabriela Kuba; Melissa P Murray; Kristen Coffey; Catarina Calle; Monica Morrow; Edi Brogi
Journal:  Mod Pathol       Date:  2021-04-06       Impact factor: 7.842

10.  PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.

Authors:  Vandna Shah; Salpie Nowinski; Dina Levi; Irek Shinomiya; Narda Kebaier Ep Chaabouni; Cheryl Gillett; Anita Grigoriadis; Trevor A Graham; Rebecca Roylance; Michael A Simpson; Sarah E Pinder; Elinor J Sawyer
Journal:  Breast Cancer Res       Date:  2017-01-17       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.